209342-41-6 Usage
Uses
Used in Pharmaceutical Industry:
Finafloxacin Hydrochloride is used as an active pharmaceutical ingredient for the treatment of bacterial infections, particularly those caused by Helicobacter pylori. It is effective in eradicating the bacteria and alleviating the associated gastroduodenal illnesses, such as peptic ulcers and gastritis.
Used in Research and Development:
Finafloxacin Hydrochloride is also utilized in the preparation of naphthyridonecarboxylic acid derivatives, which are potential drugs for the therapy of Helicobacter pylori infections. These derivatives may offer improved efficacy, reduced side effects, or enhanced targeting of the bacteria, contributing to the development of novel treatment options for patients suffering from H. pylori-related illnesses.
Check Digit Verification of cas no
The CAS Registry Mumber 209342-41-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,3,4 and 2 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 209342-41:
(8*2)+(7*0)+(6*9)+(5*3)+(4*4)+(3*2)+(2*4)+(1*1)=116
116 % 10 = 6
So 209342-41-6 is a valid CAS Registry Number.
InChI:InChI=1/C20H19FN4O4.ClH/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15;/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28);1H/t15-,16-;/m0./s1
209342-41-6Relevant academic research and scientific papers
A novel approach to Finafloxacin hydrochloride (BAY35-3377)
Hong, Jian,Zhang, Zonghua,Lei, Huoxing,Cheng, Haiying,Hu, Yufang,Yang, Wanliang,Liang, Yinglin,Das, Debasis,Chen, Shu-Hui,Li, Ge
experimental part, p. 2525 - 2528 (2009/09/06)
Finafloxacin hydrochloride, an important clinical compound was synthesized by a novel synthetic approach. An active intermediate ethyl 7-chloro-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 19 was prepared by a new route. The chiral (S,S′)-N-Boc 10 was derived from protected pyrrolidine and the absolute stereochemistry was established by X-ray analysis.
Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases
-
, (2008/06/13)
PCT No. PCT/EP97/06781 Sec. 371 Date Jun. 14, 1999 Sec. 102(e) Date Jun. 14, 1999 PCT Filed Dec. 4, 1997 PCT Pub. No. WO98/26779 PCT Pub. Date Jun. 25, 1998The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives which a
